Avalo Therapeutics Stock: BofA Sees 156% Upside with New Buy Rating Strong analyst support for abdakibart in hidradenitis suppurativa as Avalo advances to Phase 3. Credit: Avalo Therapeutics Subscribe now Already have an account? Sign in.
